Tudorza Pressair Approved for COPD2012-Jul-24 -- Scott Roberts TUESDAY, July 24 (HealthDay News) -- The Tudorza Pressair (aclidinium bromide) inhaler has been approved by the U.S. Food and Drug Administration to treat narrowing of the lung airways associated with chronic obstructive pulmonary disease (COPD) in people 18 and older. COPD, most often caused by smoking, encompasses chronic bronchitis and emphysema. Symptoms usually include chronic cough, excessive phlegm and chest tightness, the FDA said in a news release. The Tudorza Pressair inhaler, to be used twice daily, relaxes muscles around the lung's large airways, improving breathing. It is not meant to be used as a rescue inhaler during sudden asthma attacks, the agency said. Common side effects observed during clinical testing included headache, nasal inflammation and cough. The inhaler is distributed by St. Louis-based Forest Pharmaceuticals, a subsidiary of Forest Laboratories. More information Medline Plus has details about http://www.nlm.nih.... Copyright © 2012 http://www.healthday.com/. All rights reserved. The information in this article, including reference materials, are provided to you solely for educational or research purposes. Information in reference materials, are not and should not be considered professional health care advice upon which you should rely. Health care information changes rapidly and consequently, information in this article may be out of date. Questions about personal health should always be referred to a physician or other health care professional. | |